ES2981048T3 - Derivados de tiazolopirimidina fusionados como inhibidores de mnk - Google Patents

Derivados de tiazolopirimidina fusionados como inhibidores de mnk Download PDF

Info

Publication number
ES2981048T3
ES2981048T3 ES21190890T ES21190890T ES2981048T3 ES 2981048 T3 ES2981048 T3 ES 2981048T3 ES 21190890 T ES21190890 T ES 21190890T ES 21190890 T ES21190890 T ES 21190890T ES 2981048 T3 ES2981048 T3 ES 2981048T3
Authority
ES
Spain
Prior art keywords
mmol
mixture
nmr
mhz
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21190890T
Other languages
English (en)
Spanish (es)
Inventor
Jon James Winter-Holt
Edward Giles Mciver
Martin Ambler
Stephen Lewis
Joanne Osborne
Kayleigh Webb-Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
LifeArc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LifeArc filed Critical LifeArc
Application granted granted Critical
Publication of ES2981048T3 publication Critical patent/ES2981048T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES21190890T 2015-11-20 2016-11-16 Derivados de tiazolopirimidina fusionados como inhibidores de mnk Active ES2981048T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1520500.8A GB201520500D0 (en) 2015-11-20 2015-11-20 Compounds

Publications (1)

Publication Number Publication Date
ES2981048T3 true ES2981048T3 (es) 2024-10-07

Family

ID=55133106

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21190890T Active ES2981048T3 (es) 2015-11-20 2016-11-16 Derivados de tiazolopirimidina fusionados como inhibidores de mnk
ES16801016T Active ES2893154T3 (es) 2015-11-20 2016-11-16 Derivados de tiazolopirimidina fusionados como inhibidores de MNKs

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16801016T Active ES2893154T3 (es) 2015-11-20 2016-11-16 Derivados de tiazolopirimidina fusionados como inhibidores de MNKs

Country Status (9)

Country Link
US (2) US10669284B2 (enExample)
EP (2) EP3939981B1 (enExample)
JP (2) JP6928605B2 (enExample)
CN (1) CN108495855B (enExample)
AU (1) AU2016355104B2 (enExample)
CA (2) CA3240011A1 (enExample)
ES (2) ES2981048T3 (enExample)
GB (1) GB201520500D0 (enExample)
WO (1) WO2017085484A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
ES2969988T3 (es) 2017-02-14 2024-05-23 Effector Therapeutics Inc Inhibidores de Mnk sustituidos con piperidina y métodos relacionados con los mismos
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
WO2020086713A1 (en) 2018-10-24 2020-04-30 Effector Therapeutics, Inc. Crystalline forms of mnk inhibitors
CN110903286B (zh) * 2019-12-16 2021-09-24 沈阳药科大学 4,6-双取代吡啶[3,2-d]嘧啶类化合物及其制备和应用
AU2021300363A1 (en) * 2020-06-30 2023-02-09 4E Therapeutics, Inc. Pyridine-1,5-diones exhibiting MNK inhibition and their method of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US20050165029A1 (en) * 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP1724268A4 (en) 2004-02-20 2010-04-21 Kirin Pharma Kk COMPOUNDS WITH TGF-BETA-HEMMENDER EFFECT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
JPWO2005095419A1 (ja) 2004-04-01 2008-02-21 武田薬品工業株式会社 チアゾロピリミジン誘導体
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
US8633201B2 (en) * 2006-04-07 2014-01-21 Boehringer Ingelheim International Gmbh Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2008057402A2 (en) * 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2219649A2 (en) * 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
EP2331551B1 (en) * 2008-08-26 2016-06-29 Evotec International GmbH Thienopyrimidines for pharmaceutical compositions
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
JP5575274B2 (ja) * 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
EP2539343B1 (en) * 2010-02-26 2015-12-30 Evotec International GmbH Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
CN102002044A (zh) * 2010-09-29 2011-04-06 中国药科大学 嘌呤-8-酮类及噻唑并嘧啶类衍生物及其制备方法和医药用途
ES2653419T3 (es) 2013-02-01 2018-02-07 Bayer Pharma Aktiengesellschaft Pirazolopirimidinilamino-indazoles sustituidos
US9675612B2 (en) 2013-03-06 2017-06-13 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
KR20160030239A (ko) * 2013-07-08 2016-03-16 바이엘 파마 악티엔게젤샤프트 치환된 피라졸로-피리딘아민

Also Published As

Publication number Publication date
US20200247822A1 (en) 2020-08-06
CA3003559C (en) 2024-09-10
CN108495855B (zh) 2022-05-31
JP2021073306A (ja) 2021-05-13
EP3939981A1 (en) 2022-01-19
AU2016355104A1 (en) 2018-05-24
US11136338B2 (en) 2021-10-05
JP2018534314A (ja) 2018-11-22
AU2016355104B2 (en) 2021-01-28
ES2893154T3 (es) 2022-02-08
EP3377501B1 (en) 2021-08-18
US20180346483A1 (en) 2018-12-06
CA3003559A1 (en) 2017-05-26
CN108495855A (zh) 2018-09-04
US10669284B2 (en) 2020-06-02
GB201520500D0 (en) 2016-01-06
JP7181647B2 (ja) 2022-12-01
EP3939981B1 (en) 2024-04-03
EP3939981C0 (en) 2024-04-03
HK1253575A1 (en) 2019-06-21
WO2017085484A1 (en) 2017-05-26
JP6928605B2 (ja) 2021-09-01
CA3240011A1 (en) 2017-05-26
EP3377501A1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
ES2981048T3 (es) Derivados de tiazolopirimidina fusionados como inhibidores de mnk
ES2799520T3 (es) Compuestos de pirazolo[3,4-d]pirimidina o sales de los mismos
US7410966B2 (en) Use of and some novel imidazopyridines
ES2930312T3 (es) Uso de un derivado de pteridinona como inhibidor del EGFR
CN104903321B (zh) 作为激酶抑制剂的经取代三环苯并咪唑
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
JP6307088B2 (ja) キナゾリノンおよびイソキノリノン誘導体
CN113045559B (zh) 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
ES2972862T3 (es) Compuestos de pirropirimidina como inhibidores de MNK
BR112017016278B1 (pt) Uso de um composto com atividade inibitória de btk ou um sal deste para produzir um agente preventivo e/ou terapêutico para a prevenção ou tratamento de uma doença imune
HK40065647B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
HK40065647A (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
HK1253575B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
Webb-Smith 2) Patent Application Publication o Pub. No.: US 2020/0247822 A1